An investigation for investors in Supernus Pharmaceuticals Inc (NASDAQ:SUPN) shares over potential securities laws violations by Supernus Pharmaceuticals Inc was announced.
San Diego, CA -- (SBWIRE) -- 11/07/2017 -- An investigation was announced for investors in Supernus Pharmaceuticals Inc over potential securities laws violations by Supernus Pharmaceuticals.
Investors in Supernus Pharmaceuticals Inc (NASDAQ:SUPN) shares should contact the Shareholders Foundation at email@example.com or call 858-779-1554.
The investigation by a law firm focuses on whether certain statements by Supernus Pharmaceuticals regarding its business, its prospects and its operations were materially false and misleading at the time they were made.
On September 18, 2017, Supernus Pharmaceuticals Inc announced interim results for its first Phase 3 clinical trial for SPN-810. In the same release, Supernus announced it would eliminate the 18mg dose arm.
Those who purchased shares of Supernus Pharmaceuticals Inc (NASDAQ:SUPN) have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North - Suite 423
92108 San Diego
For more information on this press release visit:
Media Relations Contact
Email: Click to Email Michael Daniels